Skip to main content
Download PDF

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Journal of Hematology & Oncology volume 10, Article number: 154 (2017) Cite this article

The Original Article was published on 10 March 2016

Erratum

The original article [1] contains an error whereby Fig. 2a & b are mistakenly interchanged and contain incorrect colour-coding.

Fig. 2:
figure 1

Survival based on clinical IRC assessment by best response to romidepsin (n = 130). Progression-free survival (a) and overall survival (b). Patients with insufficient efficacy data to determine response due to early termination (NE; n = 29) were included as nonresponders. NE not evaluable

Full size image

The correct versions of Fig. 2a & b are thus displayed below.

Reference

  1. Foss F, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale Cancer Center, 333 Cedar St, TMP 3, PO Box 208028, New Haven, CT, 06520-8028, USA

    Francine Foss

  2. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Steven Horwitz

  3. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

    Barbara Pro

  4. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia

    H. Miles Prince

  5. Moffitt Cancer Center, Tampa, FL, USA

    Lubomir Sokol

  6. Veristat, LLC, Southborough, MA, USA

    Barbara Balser & Julie Wolfson

  7. Hospices Civils de Lyon, Lyon, France

    Bertrand Coiffier

Authors
  1. Francine Foss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Horwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Pro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Miles Prince
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lubomir Sokol
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara Balser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julie Wolfson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bertrand Coiffier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francine Foss.

Additional information

The online version of the original article can be found under doi:10.1186/s13045-016-0243-8

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Foss, F., Horwitz, S., Pro, B. et al. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol 10, 154 (2017). https://doi.org/10.1186/s13045-017-0518-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13045-017-0518-8

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us